"n this earnings call, West discussed their mission to keep their team members safe and ensure uninterrupted supply of high-quality containment and delivery devices required by their customers and patients. They highlighted their global operation of scale and their resources, which have allowed them to increase production capacity to meet the demand for COVID-19 vaccines and therapeutics. The company has also invested in digital technology and automation, with the goal of bringing new connected products to market and enhancing the productivity of their operations. West's financial results remain strong, with over 18% organic sales growth in the third quarter, partially offset by increased overhead costs. The company's full year 2020 net sales guidance is in a range of between $2.1 billion and $2.11 billion, with an estimated organic sales growth of approximately 14% to 15%. West's full year 2020 adjusted diluted earnings per share guidance is in a range of $4.50 to $4.55, compared to prior guidance of $4.15 to $4.25. The company is expanding their HVP manufacturing capacity at existing sites to meet"
